524322
KABRADG
Start SIP
Invest Now
Start SIP in KABRADG
Performance
- Low
- ₹32
- High
- ₹34
- 52 Week Low
- ₹11
- 52 Week High
- ₹36
- Open Price₹33
- Previous Close₹33
- Volume74,486
- 50 DMA₹29.37
- 100 DMA₹26.44
- 200 DMA₹21.71
Investment Returns
- Over 1 Month + 20.91%
- Over 3 Month + 40.31%
- Over 6 Month + 65.31%
- Over 1 Year + 218.09%
Smart Investing Starts Here Start SIP with Kabra Drugs for Steady Growth!
Kabra Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 18.5
- PEG Ratio
- 0.1
- Market Cap Cr
- 80
- P/B Ratio
- 3.1
- Average True Range
- 1.84
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 1.16
- RSI
- 62.57
- MFI
- 70.7
Kabra Drugs Financials
Kabra Drugs Technicals
EMA & SMA
Current Price
₹33.59
+
0.37
(1.11%)
- Bearish Moving Average 1
- Bullish Moving Average 15
- 20 Day
- ₹31.48
- 50 Day
- ₹29.37
- 100 Day
- ₹26.44
- 200 Day
- ₹21.71
Resistance and Support
32.91
- R3 35.64
- R2 34.65
- R1 33.90
- S1 32.16
- S2 31.17
- S3 30.42
Kabra Drugs Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-13 | Quarterly Results | |
| 2025-11-28 | Others | Inter alia, To sign an agreement with MR FRANCHISE to appoint around 200 channel partner throughout the Country for expansion. |
| 2025-11-13 | Quarterly Results | |
| 2025-10-08 | Others | Inter-aliam to consider 1.Approve the final draft of the Share Purchase Agreement (SPA) in relation to the acquisition of AMR PHARMA INDIA PRIVATE LIMITED. 2. Other business matters. |
| 2025-09-02 | Others | Inter-alia, to consider 1. Directors Report and Corporate Governance Report for the financial year 2024 -25. 2. Draft Notice calling the AGM. 3. Other business matters. |
Kabra Drugs F&O
About Kabra Drugs
- NSE Symbol
- KABRADG
- BSE Symbol
- 524322
- Managing Director
- Mr. N Aravind
- ISIN
- INE323K01017
Similar Stocks to Kabra Drugs
Kabra Drugs FAQs
Kabra Drugs share price is ₹33 As on 19 February, 2026 | 06:52
The Market Cap of Kabra Drugs is ₹79.6 Cr As on 19 February, 2026 | 06:52
The P/E ratio of Kabra Drugs is 18.5 As on 19 February, 2026 | 06:52
The PB ratio of Kabra Drugs is 3.1 As on 19 February, 2026 | 06:52
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.